Development Strategy For Harbin Pharmaceutical Group Co. Ltd. General Pharmaceutical Factory

General Pharmaceutical Factory is facing some problems, high pollution,high energy consumption, low profit margins and low technical content. They arethe shackles restricting the development of enterprises. In this case, theformulation development strategy effectively is more important for HarbinPharmaceutical Group Co. LTD. General Pharmaceutical Factory. IndustrialTransformation and Upgrading Plan(2011-2015) and Pharmaceutical Industry inthe Twelfth Five Year Plan(2011-2015) request pharmaceutical enterprises on thetransformation of the mode of development, upgrade of industrial struc ture. AndEurope puts very strict GMP standards, international import market admittancethreshold is getting higher and higher. In the worldwide, the clinical use ofantibiotics is very cautious. Antibiotic chemical raw material medicine of ourcountry exports and the growth rate of sales volume are decline. But, in recentyears, raw material medicine enterprises are developing greatly in India. There isan overtaking impetus on the production and exports against Chinesepharmaceutical raw material enterprises. When the raw material drug sales aredownturn, the main rivals concentrate on each ascendant product. So there islittle negative influence on each production and sales. Since a motley crowdsmall enterprises are optimistic about the raw materials market, some productshomogenization problem is serious. In order to grab the market, they rush to cutprice. As a result, the price is declining while the raw material and labor cost isrising. Although Harbin Pharmaceutical Group Co. LTD. General Pharmaceut icalFactory is in the leading position on the production, sales, market share ofpenicillin and the salt products, the bad fruit of low content of science andtechnology, products with low added value and low gross profit come out in2012and2013. Harbin Pharmaceutical Group Co. LTD. General PharmaceuticalFactory had deficit at the first time in2012, and it is worse in the first half yearof2013. For raw material medicine enterprises belong to high energyconsumption, high pollution industries, Harbin Pharmaceutical Group Co. LTD.General Pharmaceutical Factory of investment in environmental protection ismore and more, no matter by the state environmental protection requirements or the the international production standards. The cost of production incr easedabsolutely.